Vitamin K2 Covalently Binds to Bak and Induces Bak-Mediated Apoptosis
| Autor: | Takeshi Imai, Keisuke Miyazawa, Satoshi Sakamoto, Satoki Karasawa, Takeshi Kasama, Motoki Azuma, Yasuaki Kabe, Hiroshi Handa, Yuki Yamaguchi |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Programmed cell death
Apoptosis HL-60 Cells Biology In vivo Cell Line Tumor Humans Cysteine Pharmacology Cell Death Cytochrome c Vitamin K2 Antagonist Cytochromes c Vitamin K 2 In vitro Mitochondria Cell biology bcl-2 Homologous Antagonist-Killer Protein Proto-Oncogene Proteins c-bcl-2 Covalent bond biology.protein Molecular Medicine biological phenomena cell phenomena and immunity HeLa Cells |
| Zdroj: | Molecular Pharmacology. 83:613-620 |
| ISSN: | 1521-0111 0026-895X |
| Popis: | Vitamin K2 (VK2, menaquinone) is known to have anticancer activity in vitro and in vivo. Although its effect is thought to be mediated, at least in part, by the induction of apoptosis, the underlying molecular mechanism remains elusive. Here, we identified Bcl-2 antagonist killer 1 (Bak) as a molecular target of VK2-induced apoptosis. VK2 directly interacts with Bak and induces mitochondrial-mediated apoptosis. Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for VK2-induced cytochrome c (cyt c) release and cell death. Moreover, VK2-2,3 epoxide, an intracellular metabolite of VK2, was shown to covalently bind to the cysteine-166 residue of Bak. Several lines of evidence suggested that the covalent attachment of VK2 is critical for apoptosis induction. Thus this study reveals a specific role for Bak in mitochondria-mediated apoptosis. This study also provides insight into the anticancer effects of VK2 and suggests that Bak may be a potential target of cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|